Exploring Voting Rights and Share Capital of Nanobiotix
In the realm of corporate governance, understanding the voting rights attached to shares is crucial for investors and stakeholders alike. Nanobiotix, a pioneering biotechnology company, is fully committed to transparency in its share capital structure and voting rights.
The Significance of Voting Rights
Voting rights are essential as they empower shareholders to influence decisions regarding the company’s operations, strategy, and management. For companies like Nanobiotix, ensuring that shareholders are informed about their voting rights enhances trust and reinforces their commitment to accountability. Investors should note that the total number of outstanding shares can significantly affect their voting power.
Current Share Structure Overview
As of the latest update, Nanobiotix has reported a total of approximately 48,236,671 shares outstanding, translating into a theoretical total of 50,340,736 voting rights. Importantly, the actual exercisable voting rights stand at 50,318,618. This information is crucial for potential investors as it outlines the current landscape of ownership and influence among shareholders.
About Nanobiotix's Operations
Headquartered in Paris, France, Nanobiotix is a late-stage clinical biotechnology firm that focuses on developing groundbreaking, physics-based therapeutic approaches. Incorporated in 2003, the company aims to revolutionize treatment outcomes across various medical fields, particularly oncology. Its innovative philosophy centers around expanding the boundaries of current medical knowledge to make a significant impact on human health.
Nanobiotix's Innovative Technology
Operating in the competitive biotech sector, Nanobiotix boasts an impressive portfolio of over 25 patent families encompassing three major nanotechnology platforms. These platforms cater to different medical applications, including oncology treatments, enhancing drug delivery mechanisms, and addressing disorders of the central nervous system. This breadth of innovation positions Nanobiotix as a leader in the industry, promising improved patient outcomes through advanced treatments.
Recent Developments and Future Directions
Since its listing on the Euronext Paris in 2012 and its inclusion on the Nasdaq Global Select Market in 2020, Nanobiotix has continued to pioneer innovative solutions in the biotech landscape. The company remains actively engaged in expanding its research capabilities and clinical trials, focusing on developing new therapeutic options that can improve the lives of millions.
Contacting Nanobiotix for Further Information
Investors and interested parties can reach out to the dedicated communications and investor relations teams for more details about the company’s offerings and developments. The communications department, led by Brandon Owens, is available for inquiries at +1 (617) 852-4835 or via email at contact@nanobiotix.com.
Frequently Asked Questions
1. What are the key voting rights for shareholders of Nanobiotix?
Shareholders have the right to vote on significant corporate matters, and their voting power is determined by the number of shares they own, currently counted at around 50,318,618 exercisable rights.
2. How does Nanobiotix's share capital structure impact investors?
The structure indicates the potential influence shareholders have in decision-making processes and highlights the company's commitment to transparency.
3. What innovations is Nanobiotix focusing on?
Nanobiotix is developing advanced therapeutics leveraging nanotechnology for oncology and enhancing drug delivery mechanisms.
4. Where can I find more information about Nanobiotix?
More information about the company, its technology, and ongoing initiatives can be found on their official website at www.nanobiotix.com.
5. Who should I contact for investor-related inquiries?
For investor relations, reach out to Joanne Choi at +1 (713) 609-3150 or email investors@nanobiotix.com.
